Research Article Details
| Article ID: | A24094 |
| PMID: | 23234151 |
| Source: | Zhongguo Zhong Yao Za Zhi |
| Title: | [Clinical study on prevention efficacy of Jianpi Huatan Fang in treating non-alcoholic fatty liver disease in children]. |
| Abstract: | OBJECTIVE: To verify the clinical efficacy of Jianpi Huatan Fang in treating non-alcoholic fatty liver disease in children. METHOD: Sixty children patients with non-alcoholic liver disease were randomly assigned to 2 groups of 30 patients each , being treated with Jianpi Huatan Fang and the Vitamin E Recipe with a span of 3 months, respectively. The changes of the FINS, FPG, AST, ALT, TG, CHO, HDL, LDL, HOMA-IR, IAI after and before the treatments in both groups as well as the ultrasound imaging changes of liver were observed. RESULT: The Chinese medicine group saw higher total effective rate (83.3%) than the Vitamin E group (46.7%) with statistic difference. In addition, after the treatments, both groups saw the significant decrease of the levels of serum lipid metabolic indexes and insulin resistance indexes. Both treatments could effectively enhance the function of liver, but Chinese medicine showed better efficacy. The Chinese medicine group also saw the decrease of ATC, TG, LDL and increase of HDL-C (P < 0.05 (see character in text) P <0.01) after the treatment, showing that the Chinese medicine could effectively enhance blood fat; while the Vit E group did not showed improvement in TC, LDL-C, HDL-C. CONCLUSION: Jianpi Huatan Fang showed good efficacy in treating non-alcoholic fatty liver in children with no observable toxic side effects, thus clinic use shall be recommended. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D388 | Vitamin E | Supplement | DB00163 | NR1I2; ALOX5; DGKA | Anti-inflammatory | Under clinical trials | Details |
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |